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A workshop was held on 7–8 March 2001 in
Orlando, Florida, to review the state-of-the-
science in the application of genomic tech-
nologies in toxicology, ecotoxicology, and
molecular epidemiology and the importance
of these new developments in understanding
the potential impacts of chemicals on humans
and the environment. Ethical, legal, and regu-
latory issues and their inﬂuence on the direc-
tion and application of genomic research
were also discussed. The workshop was spon-
sored by the International Council of
Chemical Associations, which is a council of
leading trade associations representing chemi-
cal manufacturers worldwide. The workshop
was attended by more than 80 representatives
from industry, academia, and various govern-
ment agencies from the United States,
Canada, Europe, and Japan.
This report highlights the issues and recom-
mendations discussed in each of the three areas:
toxicology (including ecotoxicology), epidemi-
ology, and ethical, social, and legal issues.
Although the workshop presentations described
genomics, proteomics, metabonomics, tran-
scriptomics, and associated bioinformatics
technologies (collectively referred to in this
report as “omics”) and the applications of the
technologies for risk assessment and epidemi-
ology, the reader is referred to Corton et al.
(1999), Afshari et al. (1999), European
Centre for Ecotoxicology and Toxicology of
Chemicals (2001), and the National Institute
of Environmental Health Sciences (NIEHS),
National Center for Toxicogenomics (2001)
for background information.
Four overarching themes emerged from
the workshop:
• “Omics” technology should be used within a
framework of toxicology and epidemiology
principles so that it can be applied in a con-
text that is understood for risk assessment.
• Effective application of “omics” to epidemi-
ology studies will require suitable biologic
samples from large and diverse population
groups at relevant time periods of exposure.
• Discussion from ethical, social, and legal
perspectives highlighted the fact that the use
of “omics” technology will require the
involvement of all stakeholder communities
(i.e., research, academic, regulatory, public,
and industry).
• Recommendations for research and future
use are broadly applicable across govern-
ment, industry, and academia. A unified
research agenda as applied to toxicology and
epidemiology is urgently needed for the reg-
ulatory and scientiﬁc communities to realize
the potential power and benefits of these
new technologies.
It was recognized that “omics” have the
potential to reduce uncertainties in risk assess-
ment and facilitate rapid assessments of a
chemical’s toxic potential. However, there is a
critical need to establish relationships between
gene expression data and toxicologic changes,
enabling an integration of “omics” informa-
tion with known toxicologic measures and
other approaches to a better understanding of
mechanism of chemical effects on biologic sys-
tems. In the interim, “omics” findings will
likely be misinterpreted, because no guidelines
currently exist for correlating quantitative or
qualitative changes in gene/protein/metabolite
expression with the potential for adverse
effects. For example, are changes within cells
or tissues after chemical exposure part of the
changes associated with normal life processes
or adverse biologic effects?
“Omics” technologies are evolving
rapidly. Application of these technologies will
increase as the number of species with
genomes that have been sequenced grows and
as costs decrease. Given the speed with which
the field is evolving, standardization of
research platforms or methods does not
appear to be appropriate at this time.
However, recommendations for best practices
may need to be developed on an international
basis for research platforms or methods,
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The sequencing of the human genome has revolutionized biology and led to an astounding variety
of technologies and bioinformatics tools, enabling researchers to study expression of genes, the
function of proteins, metabolism, and genetic differences within populations and between individ-
uals. These scientiﬁc advances are making an impact in the medical research community and hold
great promise for prevention, diagnosis, and treatment of diseases. This developing ﬁeld also holds
great promise for improving the scientiﬁc basis for understanding the potential impacts of chemi-
cals on health and the environment. A workshop sponsored by the International Council of
Chemical Associations was held to review the state of the science in the application of genomics
technologies in toxicology and epidemiology. Further, consideration was given to the ethical, legal,
and regulatory issues and their inﬂuence on the direction and application of genomics technolo-
gies to environmental health research. Four overarching themes emerged from the workshop:
Genomics technologies should be used within a framework of toxicology and epidemiology princi-
ples and aplied in a context that can be used in risk assessment; effective application of these tech-
nologies to epidemiology will require suitable biologic samples from large and diverse population
groups at the relevant period of exposure; ethical, legal, and social perspectives require involve-
ment of all stakeholder communities; and a uniﬁed research agenda for genomics technologies as
applied to toxicology, epidemiology, and risk assessment is urgently needed for the regulatory and
scientiﬁc communities to realize the potential power and beneﬁts of these new technologies. Key
words: chemical industry, epidemiology, ethics, gene expression, genomics, hazard, proteomics,
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conditions and data quality.
Beneﬁts of the Application of
“Omics” to Toxicology and
Epidemiology
Common benefits of the application of
“omics” technologies for toxicology, ecotoxi-
cology, and epidemiology, as well as distinct
beneﬁts to these ﬁelds, were identiﬁed at the
workshop. Progress in achieving these bene-
ﬁts of “omics” technologies will be incremen-
tal, and large amounts of information will
have to be assimilated. Common key beneﬁts
are outlined below.
• Improved understanding of the mechanisms
of chemical action and improved under-
standing of uses and limitations of surrogate
models: “Omics” has the potential to
enhance our ability to pinpoint the molecu-
lar target(s) of toxicants, which in turn will
improve the way in which we identify
potentially hazardous chemicals, define
dose–response relationships for the induction
of toxicity, and compare responses in test sys-
tems to those relevant species of interest
(human or wildlife). Such information will
contribute to increased understanding of
mode of action and the biologic plausibility
of exposure–effect relationships. Collectively,
this increased understanding could reduce
the need to apply safety factors as uncertain-
ties associated with various aspects of the risk
assessment process are reduced [e.g., high- to
low-dose extrapolation, animal-to-human
extrapolation, extrapolation between ecologic
receptor populations (e.g., aquatic species),
extrapolation from average to susceptible
populations]. This understanding may also
lead to the development of more predictive
models of toxicity.
• Opportunity for predictive toxicology and
chemical screening: “Omics” information
should eventually help predict, for some
end points, the potential hazard of chemi-
cals within compound classes. The informa-
tion will also be useful for prioritizing
chemicals for testing. “Omics” have the
potential to contribute to predictive toxicol-
ogy approaches and, as such, may reduce
the time, cost, and use of animals for toxic-
ity evaluations. Other potential areas for
improvement are in study specificity,
dose–response assessments, demonstration
of human variability, and increased sensitiv-
ity in detecting risks. Bioinformatic tools
will be essential for defining “predictive”
gene sets from toxicogenomics studies and
will require a large reference data set that
can be broadly accessed. It will take some
time to build and interpret these data sets.
• Identiﬁcation and quantiﬁcation of suscepti-
ble populations: Human health risk assess-
ments require evaluation of susceptible
populations. For example, assessors must
address differences in the way individuals
metabolize a substance, both in the context
of the normal distribution and on the basis
of genetic polymorphisms. In the face of
uncertainties about the susceptibility of cer-
tain individuals to the toxicant, risk assessors
apply a safety factor to ensure that suscepti-
ble populations are protected. With “omics,”
we may be able to better understand the
identity, distribution, and size of the suscep-
tible population and to better characterize
the gene–environment interactions, which
will improve human health risk assessment
and improve risk management decisions. For
ecologic risk assessment, “omics” has the
potential to improve our understanding of
population susceptibility. For example, the
technology may be useful for developing
population-level (e.g., ﬁsh, invertebrates) or
community-level (e.g., microbes) metrics of
genetic susceptibility. “Omics” will also help
to identify differences in the way individuals
respond to toxicant exposures. Knowledge of
the functional impact of genetic differences
on a toxicologic response will be required,
however, before these data can be used in the
context of risk assessment. The implications
for risk assessment and protection of suscep-
tible populations are potentially signiﬁcant.
• Identification of biomarkers of chemical
exposure and effects: An important chal-
lenge in toxicology and epidemiology is
resolving the relationship between effect and
exposure. “Omics” tools should inform the
search for useful biomarkers of effect and
exposure and better characterize the relation-
ships between them, as well as detection of
risks from low levels of exposure.
Several additional beneﬁts were identiﬁed
for toxicology and epidemiology, including
generation of hypotheses through cooperative
work between epidemiologists and toxicolo-
gists, improvement of public health policy
making and public understanding of
gene–environment interactions, improvement
in understanding of attributable risks, devel-
opment of better attributable risk statements
for exposure, and development of better bio-
logic models using gene expression patterns.
Molecular Genetics in
Epidemiology
Rapid advances in molecular biology and
technologies for measuring and processing
data at the molecular level will likely affect the
use of biomarkers in population-based epi-
demiologic studies. Molecular epidemiology
studies are proliferating in the scientiﬁc litera-
ture, exploring markers of genetic damage,
genetic biomarkers of exposure, and possible
effects of gene–environment interactions.
Existing sources of human biomarker data
are being reviewed, and plans are underway
to initiate large-scale human studies to
include the collection of potential genetic
biomarkers of exposure, effect, and suscepti-
bility. The methodologic challenges underly-
ing epidemiologic studies involving human
genetic biomarkers will require careful atten-
tion and innovative statistical approaches if
the data are to be fully interpreted within the
strengths and limitations of each study. Of
particular concern are sample size (particu-
larly for testing gene–environment interac-
tions), multiple comparisons, appropriate
choice of controls, and interlaboratory vari-
ability. Although these are not new method-
ologic issues, they are particularly applicable
to these technologies and present challenges
to the validity of studies that incorporate
genetic biomarkers.
Multidisciplinary research teams will be
essential to conduct molecular epidemiology
studies that employ the new genomic tech-
nologies. There will be a greater need than
ever to evaluate the consistency between epi-
demiologic and laboratory studies. The mul-
titude of sources of inconsistency in
epidemiologic studies implies that replication
of studies will be important for inferring
causality when employing data generated
using “omics.”
Ethical, Legal, and Regulatory
Challenges
Ethical, legal, and regulatory implications
surrounding the application of genetics and
“omics” to environmental health research and
risk assessment were identified during the
workshop. The collection of genetic informa-
tion and the individualization of risk assess-
ment data will require heightened social
responsibilities on the part of organizations
and stakeholders involved in environmental
protection and risk management. Topics
addressed include the privacy of genetic infor-
mation, protection of patient conﬁdentiality,
implications for regulatory agencies, applica-
tions in tort litigation, and potential for dis-
criminatory uses of genetic information by
employers and insurers.
Technical Issues to Be Resolved
for “Omics” to Be Used
Several technical issues relating to the applica-
tion of “omics” to toxicology and epidemiol-
ogy that need to be resolved were identiﬁed:
• Technical understanding and shared learn-
ing in the public domain: Examples of suc-
cessful application of “omics” in the public
domain are needed in order to gain knowl-
edge of the utility, appropriate applications,
and methods for data analysis. It will be
important to link “omics” data to toxico-
logic and human health outcomes, distin-
guish between changes that are adaptive
responses and those that lead to adverse
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analysis methods to allow for the broad
evaluation of the data sets produced from
these studies.
• Development and availability of publicly
accessible gene expression databases: Efforts
to develop publicly accessible databases of
gene expression data are underway and need
to be continued and expanded. Two organi-
zations currently involved in developing
publicly accessible databases are the NIEHS
and the International Life Sciences Institute
(ILSI 2001). For the databases to be useful,
data quality must be assured.
• Establishment of the predictive nature of the
assays before widespread use in risk assess-
ment: “Omics” approaches will need to be
evaluated to estimate whether these methods
are actually predictive of toxicity. It has not
been determined what level of change in
gene/protein/metabolite expression will alter
phenotype (i.e., cause a toxicologic response)
and whether observed changes in gene/pro-
tein expression are causative, coincidental, or
adaptive responses to a chemical. There is a
need for proof-of-principle experiments that
will distinguish between normal physiologic
effects and toxicologic effects of a substance,
and they must be clearly anchored in con-
ventional parameters of toxicology (e.g.,
histopathology, serum enzymes). Further-
more, whether patterns of chemically
induced changes in gene expression (i.e.,
“ﬁngerprints”) are predictive of a toxicologic
response needs to be established. Generation
of “reference databases” of gene expression
changes associated with chemicals that have
well-characterized toxicologic effects, supple-
mented where possible with conﬁrmation in
molecular epidemiology studies, will be
required to establish the predictive value of
gene expression ﬁngerprints.
• Difficulty of obtaining relevant markers of
gene expression in humans: Current molecular
epidemiology studies using genetic biomarkers
are limited to easily obtainable DNA markers
of potential susceptibility (genetic polymor-
phisms). Methods to examine gene expression
products in large human populations are also
needed, but obtaining large samples of human
tissues will be problematic. An additional chal-
lenge is to examine gene expression at the time
period that is relevant to the health outcome of
interest. Recently examined gene expression
products may not be relevant to diseases that
have long latency periods.
• Absence of background prevalence data in
humans: Little information is available on
the prevalence of mutations and gene
expression patterns across various population
groups, lifestyles, and health conditions.
This information is needed for proper inter-
pretation of comparisons of gene expression
products in differently exposed populations.
Policy Issues to Be Resolved
for “Omics” to Be Used
• Privacy/conﬁdentiality/security/discrimina-
tion: There is a fear that individuals’ private
information derived through the use of
“omics” technologies will be revealed to
people or entities against the wishes of the
individuals from whom data were collected.
Furthermore, “omics” data interpretation
and disclosure may lead to discriminatory
practices. Support should be provided for
confidentiality, privacy, and security of
genetic information, as well as nondiscrimi-
natory principles and privacy issues that
ensure confidentiality and discrimination
protection.
• Lack of established principles/guidelines for
worker testing: There has been much
Congressional, media, and academic criti-
cism of genetic testing in an occupational
context. Although some private industries
have been sued for inappropriate genetic
testing of their employees, others have been
sued for not performing or recommending
genetic testing of their workers or product
users. Therefore, a set of clear principles and
professional guidelines should be developed
with respect to genetic testing of workers
and should include educational outreach
within industry sectors.
• Lack of counseling for coping with genetic
information: Many people may not want to
know their own genetic information, and
those who do learn about it may need
counseling to understand the implications.
There may be a need for increased empha-
sis on counseling and the availability of
trained professionals to assist people in
understanding and coping with their
genetic information.
• Advice needed for social and ethical issues:
Social and ethical issues need to be explic-
itly addressed at the forefront of the devel-
opment and use of these technologies. The
common rule for human research (Health
Research Extension Act of 1985) and subse-
quent regulation (DHHS 1991), which
impose certain requirements for federally
funded research, including requirements for
informed consent and review of research
proposals by institutional review boards,
should be widely adopted.
• Premature use of “omics” data: Because of
the excitement surrounding the discovery of
a new technology, some people may use
information based on “omics” data (e.g., in
hazard assessment) before its effectiveness is
proven. A certain amount of guidance for
tests and results is needed to ensure that
misrepresentation and misinterpretation of
data do not occur. Premature use of
genomics data and technology may lead to a
false sense of risk and/or security.
• Uncertainty of regulatory positions on
genomics data: It is unclear how regulatory
agencies will consider and use “omics”
information for risk assessment and decision
making, given that the predictive nature of
the assays has not yet been established. The
extent to which “omics” data will be consid-
ered or incorporated into safety, hazard, or
risk assessments is unknown at this time.
There is a concern that there might be pre-
mature interpretation on the part of regula-
tors. There should be a concerted effort to
aid government agencies in developing
approaches and the use of these technolo-
gies. The development of multistakeholder
guidelines for use of “omics” techniques and
data would facilitate good “omics” practices,
as would scheduling periodic workshops to
provide technical updates, explaining how
“omics” information can be used when
making regulatory decisions, and support-
ing scientiﬁc and policy resources related to
“omics” within federal agencies.
• Other issues: Additional items were identi-
fied, including the potential for fraud and
misrepresentations, legally mandated disclo-
sures, false positives, proliferation of agency
mandates/targets, statutes that do not reﬂect
technologic advances, and inequities as a
result of limited access to testing.
Recommendations for
Research
Although workshop recommendations were
given in the context of the chemical industry,
the recommendations for research and future
use are broadly applicable across government,
industry, and academia and will only be
achieved by all stakeholders working together.
A uniﬁed research agenda as applied to toxi-
cology and epidemiology is urgently needed
to realize the potential power and beneﬁts of
these new technologies.
Recommendations in the areas of toxico-
logic research and epidemiologic research
were provided as follows:
• Research recommendations for toxicology:
Examples/case studies and research projects
that evaluate how “omics” can improve risk
assessment will be achieved by studying
compounds that have well-established toxi-
cologic profiles. Good examples or studies
will a) demonstrate how “omics” technolo-
gies elucidate mechanism of action and dose
response (this topic is top priority), b) link
“omics” information to traditional toxicity
tests and end points, c) establish the rele-
vance of an “omics” response to phenotype
(e.g., distinguish between adaptive and
adverse responses), and d) demonstrate how
“omics” can reduce uncertainties associated
with animal-to-human extrapolation.
• Research recommendations for epidemiology:
Research should a) characterize prevalence
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morphisms and their functions, b) focus on
ﬁnding methods to assess gene expression in
large numbers of people, c) address the sta-
tistical and bioinformatics issues, and d)
pursue a multidisciplinary approach to epi-
demiology research and development.
Summary
In summary, the workshop discussions recog-
nized the great value and potential that
“omics” has for improving toxicology,
epidemiology, risk assessment, and the pro-
tection of human health and the environment
but cautioned that the technology should be
validated and applied according to the princi-
ples of toxicology and epidemiology. The
applications of “omics” present issues that
will require research and collaborative efforts
on the part of all stakeholders to resolve.
REFERENCES
Afshari CA, Nuwaysir EF, Barrett JC. 1999. Application of com-
plementary DNA microarray technology to carcinogen
identification, toxicology, and drug safety evaluation.
Cancer Res 59(19):4759–4760.
Corton JC, Anderson SP, Stauber AJ, Janszen DK, Kimbell JS,
Conolly RB. 1999. Entering the era of toxicogenomics with
DNA microarrays. CIIT Act 19:1–9.
DHHS. 1991. Protection of Human Subjects. Title 45 CFR, Part
46. Washington, DC: U.S. Department of Health and
Human Services. Available: http://ohsr.od.nih.gov/mpa
[accessed 29 July 2002].
ECETOC. 2001. White Paper on Genomics, Transcript Proﬁling,
Proteomics, and Metabonomics (GTPM). ECETOC
Document No. 42. Brussels, Belgium: European Centre for
Ecotoxicology and Toxicology of Chemicals.
Health Research Extension Act of 1985. Public Law 99–158,
1985. Available: http://thomas.loc.gov [accessed 29 July
2002].
ILSI. 2001. ILSI/HESI Alternatives to Carcinogenicity Testing
Project. Toxicol Pathol 29(suppl):1–351.
NIEHS, National Center for Toxicogenomics. 2001. NCT
Overview. Available: http://www.niehs.nih.gov/nct/
concept.htm [cited 2 October 2001].
Meeting Report • Henry et al.
1050 VOLUME 110 | NUMBER 10 | October 2002 • Environmental Health Perspectives